GBS are a major cause of systemic infections in newborn infants, with a case fatality rate of 20-50% and a frequency of neurologic sequelae of about 30% in infants with meningitis (6, 10, 14, 17) . The disease seems to be correlated with a relative deficiency of maternal antibodies to GBS-type antigens (2, 5, 16, 25, 37) . For this reason, attention has been focused on immuneprophylaxis of the disease using vaccination (1) and administration of specific IgG antibodies to pregnant women and/or their infants.
GBS are divided into five types (Ia, Ib, Ic, 11, and 111) on the basis of mouse-protection tests (19, 20, 36) . Type Ic shares the Ia carbohydrate antigen with type Ia and the Ibc protein with type Ib, whereas the other four types are characterized by unique carbohydrate antigens (36) . Antibodies against each of these antigens protect mice from infection with GBS carrying the respective antigen. Recently, Lindtn (22) demonstrated that antibodies to another antigen, R-protein, protected mice against infection with type I1 strains carrying this structure (22) . Rprotein, which can also be detected within groups A, C, G and L streptococci (22) , had been hitherto considered to be of no importance with regard to the virulence of GBS and, therefore, has been the subject of only a few studies.
A recent study indicated that a majority of mothers of GBSinfected infants are poor responders to bacterial carbohydrate antigens (7) . One study on genetic markers of human IgG (Gm allotypes) suggested that this relative deficiency might have a genetic basis (1 5); thus, the prospects of giving successful prophylactic treatment by vaccination appear to be rather slim. On the other hand, a number of studies have been published concerning the protective effect of gammaglobulin preparations in experimental GBS-infections. Three animal species have been used: chicken embryos (38) , neonatal rats (1 1, 12, 29) and mice (3, 13, 34) . Most interest has been focused on carbohydrate antigens, in particular type I11 antigen (3, 1 1, 12, 13,29), whereas few studies concerning types Ia, Ib and I1 have been reported (34, 38) . With one exception (3), the studies showed a protective effect of gammaglobulin (1 1, 12, 13, 29, 34, 38) . Data concerning the Ibc protein and R-protein are not yet available.
Beneficial effects of the administration of gammaglobulin in newborn infants were reported in a non-controlled study (31) . The present paper concerns the protective effect on mice of four different gammaglobulin batches, using six different GBS strains. The results indicate differences between the batches that might be attributable to a varying content of antibodies to GBS antigens, in particular protein antigens.
MATERIALS AND METHODS
Gammaglobulin batches. The following three batches of gammaglobulin (Sandoglobulin, for intravenous administration) (3 1) were kindly supplied by Sandoz Produkte AG (Basel): batch no. I (2.36 1.002.0), no. I1 (0.36 1.002.0), and no. I11 (2.36 1.800.0). The preparations were supplied lyophilized and dissolved in the accompanying solvent (isotonic saline) to a stock concentration of 82.5 g/l. Further dilutions were prepared in saline.
Gammaglobulin Kabi, 165 g/l, was purchased from AB Kabi (Stockholm) (batch no. IV, 77367, for intramuscular use). Further dilutions were prepared in saline. The IgA content in the four batches was quantitated using electroimmunoassay with specific antiserum against IgA (2 1).
Mouse-protection tests. The following GBS strains isolated from blood or cerebrospinal fluid specimens from infants with neonatal septicemia/meningitis were used: type Ia, strain no. W25260; type Ib, strain no. 207; type 11, R-protein negative (11, R-), strain no. W25 12 1; type 11, R-protein positive (11, R+), strain no. 02038; type 111, R-, strain no. W25062; and type 111, R+, strain no. D052. The strains were grouped and typed as described previously (4) . The six mothers of the GBS-infected infants, from whom the strains were isolated, had low serum levels of IgG antibodies against the type of GBS infecting their infants.
Inocula of the strains for mouse-protection tests were prepared as described for group A streptococci by Sramek (33), i.e., the bacteria in log phase were frozen at -80°C until use. The mouseprotection tests were performed as described previously (24) .
Female adult NMRI mice (weight, 18-20 g) were purchased from Anticimex (Stockholm). The bacteria (0.5 ml) and gammaglobulin (1.0 ml) were injected intraperitoneally using a separate syringe for each preparation. The gammaglobulin was injected immediately before the bacteria. The animals were observed for 96 h after challenge.
Before testing of the protective effect of the gammaglobulin preparations, the amount of bacteria needed to kill at least five out of 10 mice was titrated; it was found essential to use a minimal dose of bacteria because the protective effect of gammaglobulin decreased rapidly with increasing dose of bacteria.
Control groups of mice received saline instead of gammaglobulin. Fisher's exact test was used in the statistical analysis of the results.
Quantitation of anti-GBS antibodies. Quantitation of anti-
bodies against whole bacteria of types Ia, Ib, 11, and I11 GBS was performed using ['251]-labeled protein A of Staphylococcus aureus, as described previously (5). In brief, the preparations to be tested were absorbed with a GBS strain without type antigens (No. 848, kindly supplied by the State Serum Institute, Copenhagen) and the antibodies against surface antigens of the corresponding type were then quantitated using radiolabeled protein A. Protein A binds to the Fc-part of human IgG 1, 2 and 4 (1 8).
In some experiments, anti-human IgG3 serum (kindly supplied by Dr. A. Grubb, Malmo General Hospital, Sweden) was added, as described previously (25) , in order to investigate the gammaglobulins with regard to antibodies to type I1 GBS belonging to the human subclass IgG3.
In order to estimate antibodies against type Ib carbohydrate antigen, the gammaglobulin batches were absorbed with strain No. 848 and the antibodies against trypsinized Ib were then quantitated. Trypsin treatment, which was performed as previously described (5), removes the Ibc protein (20, 36) . For quantitation of antibodies against the Ibc protein, the gammaglobulin batches were absorbed with trypsinized Ib GBS as described previously ( 3 , followed by quantitation of antibodies against untrypsinized type Ib GBS. Antibodies to R-protein were determined as previously described, using protein A (25) .
Two human sera, L and H, were used throughout the studies to compare with the gammaglobulin batches. These sera represented "low" (L) and "high" (H) levels for all GBS-type antigens, as judged by tests on sera from pregnant GBS camers giving birth to healthy infants (6, 8) .
All tests were performed with gammaglobulin at a concentration of 10.3 g/l, corresponding to the level in human serum. The tests were performed in duplicate and the results are expressed in cpm. The difference between the duplicates did not exceed 10% of their mean value in any case. The background of the tests did not exceed 100 cpm, as tested with rabbit preimmune serum.
IgG antibodies to type 111, R-GBS in the gammaglobulin batches were also determined, using ELISA. Before testing, the preparations were absorbed with strain 848. The procedure for quantitation of antibodies in the absorbed batches followed the method described by Polin et al. (28) . Type I1 GBS (strain No. W25062) was pepsin-treated in order to remove surface protein (28) and used for coating of the microtitre plates. Monospecific antihuman IgG-alkaline phosphatase conjugates were purchased from Orion Diagnostics AB (Trosa, Sweden). Results were determined photometrically at 405 nm using a Titertec Multiscan (Flow Laboratories, Solna, Sweden). Titres were expressed as the absorbance value of the respective preparation tested.
RESULTS
The antibody levels in the four gammaglobulin batches were compared with the antibody content in two human sera (H and L), using radiolabeled protein A. All batches contained greater amounts of antibody to whole type Ia GBS than serum H (Table  1) . Batch I contained more antibodies to type Ia than did batch IV (2070 and 1770 cpm, respectively). Batches I, 11, and 111 gave intermediate values for antibodies to whole-type Ib GBS, whereas batch IV promoted an uptake of radioactivity corresponding to serum L. All four batches were remarkably low in antibodies against type 11, R-GBS, only about 200 cpm above serum L. The batches showed high levels of antibodies to type 111, R-GBS, with batch I showing 200 cpm more than the other batches. Using the ELISA technique, it was also not possible to demonstrate any differences with respect to antibodies against pepsinized type 111, R-GBS (Fig. 1) .
In order to test the possibility that the anti-type I1 antibodies in the gammaglobulin batches not detectable by protein A belonged to the IgG3 subclass, a specific rabbit anti-IgG3 serum was added to the test system for anti-type I1 and anti-Ia antibodies. Only a slight increase (5-10%) in binding of protein A was observed with the four batches.
Quantitation of antibodies to Ibc-protein and R-protein using radiolabeled protein A are also given in Table 1 . Batch IV contained only 50% of the antibodies to Ibc-protein found in batches I, 11, and 111. The level of antibodies to R-protein was also lower, about 30%, in batch IV than in the other batches.
Twofold dilutions of the four batches, ranging from 82.5-1.3 g/l, were tested for capacity to protect mice from infection with type 111, R-GBS (Table 2) . Each dilution was given to 10 mice, 1 ml intraperitoneally/mouse, immediately before lo7 CFU of the test strain. Compared with 20 control mice, of which 19 died, batch I afforded significant protection at a concentration of 1.3 g/l, corresponding to 1.3 mg/mouse. Batches I1 and 111 afforded protection at a concentration of 2.6 g/l. Batch IV was protective at a concentration of 5.2 g/l.
Batches I and IV, 10 ml of each at a concentration of 41.3 g/ 1, were absorbed with the pellet from 1 litre overnight culture of type 111, R-GBS in Todd Hewitt broth at 37°C. None of the batches gave significant protection against type 111, R-GBS after the absorption. The amount of bacteria given to the mice was found to be important. When the dose of bacteria was raised to 5 x lo7 CFU/mouse batch IV gave no protection at a concentration of 82.5 g/l.
All four batches of gammaglobulin were tested for toxicity to mice by injecting groups of 10 mice with gammaglobulin, 82.5 g/l; none of the animals died. The capacity of batches I and IV to protect mice against GBS types Ia, Ib, 11, R-, 11, R+, and 111, R+ was also studied. The gammaglobulin batches were tested at the concentrations 41.3, 20.6, 5.2 and 1.3 g/l. Batch I protected at a concentration of 1.3 g/l against type Ia, whereas the lowest effective concentration of batch IV was 5.2 g/l ( Table 3 ). The corresponding concentrations of batches I and IV for protection against type Ib were 5.2 and 20.6 g/l. None of the concentrations of batch IV tested was effective against type 111, R+, in contrast to batch I which was protective at 20.6 g/l. None of the batches was protective against types 11, R+ and 11, R-.
Among the animals not protected by gammaglobulin against the various strains, heart blood was collected from 20 randomly selected mice; all specimens grew the type of GBS injected. Batches I, I1 and I11 contained 2% (w/w) IgA, whereas no IgA was detected in batch IV. Test of gammaglobulin batches I-IV for antibodies to pepsinized type 111, R-group B streptococci (GBS) using enzyme-linked immunosorbent assay technique. Abscissa, dilution of respective batch tested. Ordinate, absorbance measured at 405 nm at end of test. H and L denote the values for two normal sera tested at dilution 1:24. The two sera represent the highest and lowest values, respectively, of sera from GBS-carriers giving birth to healthy infants, tested for antibodies to GBS, type 111, R-using radiolabeled protein A. 
DISCUSSION
The general picture that emerged from the quantitation of antibodies in the gammaglobulin batches by using radiolabeled protein A depicts a close correlation between the antibody levels and the results of the mouse protection tests. Batch I contained more antibodies against type Ia than batch IV (Table 1) : accordingly, the animal protective concentrations were 1.3 and 5.2 g/l, respectively ( Table 3 ). The protective levels of batches I and IV against type Ib GBS were 5.2 and 20.6 g/l, respectively, corresponding to antibody levels of 1350 and 940 cpm, respectively. All four batches showed remarkably low levels of antibodies against type I1 GBS carbohydrate antigen and none of the preparations were mouse-protective against this type. The antibody level against type 111, R-was 1640 cpm for batch I, vis-5-vis 1360-1420 for batches 11-IV. In mouse-protection tests the protective level of batch I was 1.3 g/l, in contrast to batches I1 and I11 which gave protection at 2.6 g/l and batch IV with a protective level of 5.2 g/l ( Table 2 ). This demonstrated again a correlation between antibody levels and mouse protection. Most studies by others were concerned with the correlation between mouse protection and in vitro phagocytic assays (1 1, 12, 13, 29, 34, 38) .
Batch I showed a greater protective capacity for types Ia, Ib, 111, R-, and 111, R+ than did batch IV (Tables 2, 3 ). Batches I1 * Each mouse received 0.5 ml bacteria containing lo7 CFU and 1 ml gammaglobulin (study groups) or 1 ml saline (controls). The study groups consisted of 10 mice each. The control group consisted of 20 mice, of which only one survived.
t Study group compared with the control group.
and 111 were also more efficient in protecting against type 111, R-than was batch IV (Table 2 ). Batches I, 11, and I11 had higher levels of antibodies to the Ibc-protein and R-protein than batch IV (Table I) . On the other hand, the ELISA technique did not demonstrate any differences between the four batches with respect to antibodies against pepsinized type 111, R-GBS. The main differences between batches I, 11, and 111, on the one hand, and batch IV, on the other, appear to concern antibodies to protein antigens and the content of IgA (not detectable in batch IV). The procedure used to remove IgA from batch IV may have resulted in the disappearance of IgG antibodies to protein antigens. Testing with gammaglobulin prepared in accordance with the manufacturing procedure for batches 1-111 indicated a normal distribution of subclasses as compared with human sera (32) whereas batch IV lacked IgG4 (V.A. Oxelius, personal communication). The details of the manufacturing procedures are unknown to us. The differences between the protective effect of gammaglobulin preparations against type 111, R-and type 111, R+ (Tables 2  and 3 ) may indicate that R-protein is of importance for the virulence of GBS in mice. We have previously found that antibodies to R-protein can be protective against type 11, R+ (22) and that mothers of infants infected with R+ GBS stains have low levels of antibodies to R-protein (25) . In clinical isolates from our district, 5 1 % of tvve I1 strains and 86% of tvDe 111 strains camed R-protein (i6). Shigeoka et al. (30) described differences between type I11 strains with respect to resistance against opsonization with human antibodies. They also demonstrated that pepsin treatment of the resistant strains rendered the bacteria more susceptible to in vitro opsonization (30) . The role of R-protein in this context remains to be elucidated.
There are still many important questions concerning the "translation" of mouse-protection tests to human GBS neonatal infections. GBS infection do not occur naturally in mice. Furthermore, the route of acquisition of GBS in neonatal septicemia is probably by the airways, which is an important difference from the mouse model where the bacteria are injected intraperitoneally. Little is known about the number of bacteria present in the blood stream during neonatal GBS septicemia. Probably, no amount of appropriate antibody will protect the human baby during the later stages of septicemia, and administration of gammaglobulin will only be a complement to antibiotics. This was illustrated by the finding that the Ig required for protection in the mouse model was highly dependent of the infecting dose of bacteria. The Ig required for protection is highly dependent of this dose. Only 5.2 mg of batch IV protected mice against lo7 type 111, R-GBS, whereas 82.5 mg of the same batch did not * Each mouse received 0.5 ml bacteria and 1 ml gammaglobulin (study groups) or 1 ml saline (control groups). The challenge doses were for type Ia, lo6 CFU; type Ib, lo7 CFU; type 11, R-, 10' CFU; type 11, R+, 10' CFU; and type 111, R+, 10' CFU. The study groups consisted of 10 mice each.
protect against 5 X lo7 CFU of the same bacteria. It might be, therefore, misleading to calculate protective levels of gammaglobulin based on body weight only. The relationship between the amount of antibody and infecting dose might be more important. Studies on complement activation indicate that small amounts of specific antibodies coated on GBS type 111 activate the classical pathway whereas larger amounts recruite the alternative pathway (9) .
The mouse-protection tests demonstrated that gammaglobulin batch I protected against type Ia and type 111, R-GBS at a low concentration, 1.3 g/l, corresponding to 65 mg/kg mouse weight (Tables 2 and 3 ). The amount of batch I necessary to protect against type Ib was 5.2 g/l, or 260 mg/kg, and for type 111, R+, 20.6 g/l or 1030 mg/kg. With all the above reservations for the translation to neonatal infants, it would seem that between 0.2-3.0 g of batch I is sufficient to protect a newborn infant weighing 3000 g against infections with GBS types Ia, Ib and 111. On the other hand, neither batch I nor batch IV offered any mouse protection against type 11, R-and 11, R+ GBS.
The distribution of GBS types involved in neonatal septicemia/meningitis varies from one geographic region to another (27) . In some American reports type 111 dominates (35) whereas the strains isolated in Sweden reflect the distribution of types in the urogenital tract of the parturients (7, 8) . Among 41 strains isolated from cases of neonatal septicemia, eight belonged to type la, six to type Ib, eight to type 11, and 19 to type 111 (23) . We consider it important to include all serotypes in the planning of immunotherapy against neonatal GBS infection.
In conclusion. the vresent studv demonstrates the imvortance of antibodies to' antigens in preventing GBS iAfections in mice and confirms other reports indicating that gammaglobulin may play a role in the prevention and treatment of neonatal GBS infections. The possibility that antibodies to protein antigens might be lost during removal of IgA from human gammaglobulin batches needs further elucidation. Finally, the correlation found between mouse protection tests and antibody quantitation by radiolabeled protein A strengthens the clinical relevance of this method.
